Argos Therapeutics’ Arcelis™ HIV Immunotherapy Demonstrates Significant Reduction in Viral Load and Delay in Viral Rebound Kinetics in Interim Analysis of Phase 2 Study

Argos announced that its Arcelis HIV immunotherapy demonstrated a significant reduction in viral load in interim analysis of its Phase 2 study.... [more]

View complete Press Release article